-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
HCV-IN-31
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1998705-62-6.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1998705-62-6 |
| Description | HCV-IN-31 is an inhibitor of HCV, with an EC50/EC95 of 15.7 μM for HCV replicon. |
Product Information
| Synonyms | (2R,3R,4R,5R)-5-(2-amino-6-(methylamino)-9H-purin-9-yl)-4-fluoro-2-(hydroxymethyl)-4-methyltetrahydrofuran-3-ol; Adenosine, 2-amino-2'-deoxy-2'-fluoro-N,2'-dimethyl-, (2'R)-; 2-Amino-2'-deoxy-2'-fluoro-N,2'-dimethyladenosine |
| IUPAC Name | (2R,3R,4R,5R)-5-[2-amino-6-(methylamino)purin-9-yl]-4-fluoro-2-(hydroxymethyl)-4-methyloxolan-3-ol |
| Molecular Weight | 312.30 |
| Molecular Formula | C12H17FN6O3 |
| Canonical SMILES | CC1(C(C(OC1N2C=NC3=C(N=C(N=C32)N)NC)CO)O)F |
| InChI | InChI=1S/C12H17FN6O3/c1-12(13)7(21)5(3-20)22-10(12)19-4-16-6-8(15-2)17-11(14)18-9(6)19/h4-5,7,10,20-21H,3H2,1-2H3,(H3,14,15,17,18)/t5-,7-,10-,12-/m1/s1 |
| InChIKey | HPINXBYYNVDDEB-GSWPYSDESA-N |
| Boiling Point | 685.1±65.0°C at 760 mmHg |
| Purity | ≥95% |
| Density | 1.8±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | White to off-white (Solid) |
| Storage | Store at 2-8°C, protect from light |
| Complexity | 420 |
| Exact Mass | 312.13461659 |
| Target | EC50: 0.010 ± 0.004 μM (HCV) |
| XLogP3-AA | 0.4 |